|
|||||
|
|
Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria,April 2022 |
|
| Authors: | Sonja Pleininger Alexander Indra Daniel Golparian Florian Heger Stefanie Schindler Susanne Jacobsson Stefan Heidler Magnus Unemo |
| Affiliation: | 1.Austrian Agency for Health and Food Safety, Vienna, Austria; 2.WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; 3.Urology Department, LKH Hochsteiermark, Leoben, Austria; 4.Institute for Global Health, University College London, London, United Kingdom |
| Abstract: | We describe a gonorrhoea case with ceftriaxone plus high-level azithromycin resistance. In April 2022, an Austrian heterosexual male was diagnosed with gonorrhoea after sexual intercourse with a female sex worker in Cambodia. Recommended treatment with ceftriaxone (1 g) plus azithromycin (1.5 g) possibly failed. Worryingly, this is the second strain in an Asian Neisseria gonorrhoeae genomic sublineage including high-level azithromycin-resistant strains that developed ceftriaxone resistance by acquisition of mosaic penA-60.001. Enhanced resistance surveillance and actions are imperative to prevent spread. |
| Keywords: | Neisseria gonorrhoeae extensively drug-resistant XDR ceftriaxone resistance high-level azithromycin resistance |